Maria Moreno Selected Research

3,5-diiodothyronine

1/2019	3,5-Diiodo-L-Thyronine Exerts Metabolically Favorable Effects on Visceral Adipose Tissue of Rats Receiving a High-Fat Diet.
1/2018	3,5-Diiodo-L-Thyronine Affects Structural and Metabolic Features of Skeletal Muscle Mitochondria in High-Fat-Diet Fed Rats Producing a Co-adaptation to the Glycolytic Fiber Phenotype.
1/2018	Differential Effects of 3,5-Diiodo-L-Thyronine and 3,5,3'-Triiodo-L-Thyronine On Mitochondrial Respiratory Pathways in Liver from Hypothyroid Rats.
1/2016	3,5,3'-Triiodo-L-Thyronine- and 3,5-Diiodo-L-Thyronine- Affected Metabolic Pathways in Liver of LDL Receptor Deficient Mice.
3/2014	Thyroid hormone analogues and derivatives: Actions in fatty liver.
11/2011	Nonthyrotoxic prevention of diet-induced insulin resistance by 3,5-diiodo-L-thyronine in rats.
10/2011	3,5-Diiodo-L-thyronine prevents high-fat-diet-induced insulin resistance in rat skeletal muscle through metabolic and structural adaptations.
11/2010	Pathways affected by 3,5-diiodo-l-thyronine in liver of high fat-fed rats: evidence from two-dimensional electrophoresis, blue-native PAGE, and mass spectrometry.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Maria Moreno Research Topics

Disease

10	Insulin Resistance 01/2022 - 01/2008
9	Neoplasms (Cancer) 12/2018 - 11/2003
6	Obesity 02/2016 - 02/2009
4	Inflammation (Inflammations) 01/2022 - 10/2007
4	Fatty Liver 01/2019 - 09/2005
4	Overweight 01/2019 - 09/2005
3	Body Weight (Weight, Body) 01/2019 - 09/2005
3	Melanoma (Melanoma, Malignant) 01/2015 - 09/2011
3	Weight Loss (Weight Reduction) 11/2014 - 03/2014
2	Hypothyroidism 01/2018 - 11/2012
2	Adenocarcinoma 07/2011 - 12/2007
1	Seizures (Absence Seizure) 03/2020
1	Central Nervous System Diseases (CNS Diseases) 04/2019
1	Neurodegenerative Diseases (Neurodegenerative Disease) 04/2019
1	Weight Gain 01/2019
1	Communicable Diseases (Infectious Diseases) 12/2018
1	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/2016
1	Thyrotoxicosis 01/2016
1	Type 2 Diabetes Mellitus (MODY) 11/2014
1	Dyslipidemias (Dyslipidemia) 03/2014
1	Metabolic Diseases (Metabolic Disease) 07/2013
1	Colonic Neoplasms (Colon Cancer) 07/2011
1	Carcinoma (Carcinomatosis) 07/2011
1	Residual Neoplasm 07/2011
1	Overnutrition 09/2010

Drug/Important Bio-Agent (IBA)

8	3,5-diiodothyronineIBA 01/2019 - 11/2010
8	LipidsIBA 01/2019 - 09/2005
4	Thyroid HormonesIBA 01/2019 - 03/2014
4	Peptides (Polypeptides)IBA 01/2015 - 11/2003
3	Insulin (Novolin)FDA Link 01/2022 - 04/2014
3	AcidsIBA 01/2019 - 09/2005
3	Fatty Acids (Saturated Fatty Acids)IBA 01/2019 - 02/2009
3	CholesterolIBA 02/2016 - 09/2005
3	Thyroid Hormone Receptors (Thyroid Hormone Receptor)IBA 11/2014 - 02/2009
2	Triglycerides (Triacylglycerol)IBA 01/2022 - 09/2005
2	Uncoupling Protein 3IBA 01/2022 - 01/2011
2	Glucose (Dextrose)FDA LinkGeneric 01/2019 - 11/2014
2	AntigensIBA 12/2018 - 07/2011
2	Proteins (Proteins, Gene)FDA Link 01/2018 - 04/2014
2	IronIBA 02/2016 - 04/2014
2	TRC150094IBA 03/2014 - 07/2012
2	Sirtuin 1IBA 07/2013 - 11/2011
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2013 - 11/2003
1	AdipokinesIBA 01/2022
1	Medical MarijuanaIBA 03/2020
1	Single-Domain AntibodiesIBA 04/2019
1	Hormones (Hormone)IBA 01/2019
1	Oleic Acid (Oleate)IBA 01/2019
1	ThyroninesIBA 01/2019
1	EnzymesIBA 01/2019
1	PalmitatesIBA 01/2019
1	Propylthiouracil FDA Link 01/2018
1	Protons (Proton)IBA 01/2018
1	Iopanoic Acid (Telepaque)FDA Link 01/2018
1	Apolipoproteins B (ApoB)IBA 01/2016
1	VLDL LipoproteinsIBA 01/2016
1	LDL CholesterolIBA 01/2016
1	ApolipoproteinsIBA 01/2016
1	LDL Receptors (LDL Receptor)IBA 01/2016
1	EDDA (NiEDDA)IBA 01/2015
1	tricineIBA 01/2015
1	alpha-MSHIBA 01/2015
1	Chelating AgentsIBA 01/2015
1	LactamsIBA 01/2015
1	LigandsIBA 01/2015
1	Melanocyte-Stimulating Hormones (MSH)IBA 01/2015
1	Type 1 Melanocortin ReceptorIBA 01/2015
1	Crystallins (Crystallin)IBA 11/2014
1	Thyroid Hormone-Binding ProteinsIBA 11/2014
1	Transferrin (beta 2 Transferrin)IBA 04/2014
1	metal transporting protein 1 (ferroportin)IBA 04/2014
1	Messenger RNA (mRNA)IBA 04/2014
1	Ferritins (Ferritin)IBA 04/2014
1	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 03/2014
1	2- ((3,5- dimethyl- 4- (4'- hydroxy- 3'- isopropylbenzyl)phenoxy)methyl)- 4- (3- chlorophenyl)- 2- oxido(1,3,2)dioxaphosphonaneIBA 03/2014
1	Thyroxine (Levothyroxine)FDA LinkGeneric 03/2014
1	Protein Isoforms (Isoforms)IBA 03/2014
1	AMP-Activated Protein KinasesIBA 07/2013
1	Bevacizumab (Avastin)FDA Link 01/2013
1	technetium 99m tricarbonyl bevacizumabIBA 01/2013
1	Nonesterified Fatty Acids (NEFA)IBA 11/2012
1	AminesIBA 09/2011
1	Dendrimers (Dendrons)IBA 09/2011
1	Technetium (Technetium 99m)IBA 09/2011
1	Immunoglobulin G (IgG)IBA 07/2011
1	GlycopeptidesIBA 07/2011
1	MucinsIBA 07/2011
1	AntibodiesIBA 07/2011
1	Combined VaccinesIBA 07/2011
1	Biological ProductsIBA 09/2010
1	Glycerolphosphate Dehydrogenase (Glycerol 3 Phosphate Dehydrogenase)IBA 02/2009
1	Glycerol (Glycerine)FDA LinkGeneric 02/2009
1	PPAR deltaIBA 01/2008
1	amatuximabIBA 12/2007

Therapy/Procedure

2	Bariatric Surgery 11/2014 - 04/2014
1	Therapeutics 04/2019
1	Fat-Restricted Diet (Diet, Fat Restricted) 01/2019
1	Subcutaneous Injections 12/2018
1	Immunotherapy 07/2011
1	Drug Therapy (Chemotherapy) 12/2007